The Always-On MSL: How AI Is Reshaping Pharma-Physician Engagement

SCOTTSDALE, Ariz. – August 11, 2026 – The pharmaceutical industry's long-standing model of physician engagement—built on armies of field-based representatives and constrained by geography and the 9-to-5 workday—may be facing its most significant disruption yet. Prismic-AI, a division of Prismic Corporation, today launched Veritas24-7, an enterprise platform that promises to give physicians on-demand, 24/7 access to AI-powered, "lifelike" personas of a company's sales and medical affairs teams.

The platform aims to solve a fundamental logistics problem for the life sciences sector: how to provide timely, accurate, and compliant information to busy clinicians whenever and wherever they need it. By creating digital twins of Medical Science Liaisons (MSLs) and Sales Representatives, Prismic-AI is betting that technology can extend the reach and impact of human expertise far beyond its traditional limits.

"For decades, pharmaceutical companies have invested heavily in Medical Science Liaison and Sales organizations, yet physician access to that expertise has often remained limited by geography and business hours," said Peter Moriarty, Founder and Chief Executive Officer of Prismic Corporation, in the announcement. "Veritas24-7 changes that."

The vision is ambitious, placing AI not in the background as an analytical engine, but on the front lines, engaging directly with healthcare professionals in what the company describes as "natural, face-to-face, two-way conversations." This move from data-cruncher to digital colleague marks a critical inflection point, one that carries immense potential alongside profound regulatory and ethical questions.

From Human Rep to Digital Persona

At its core, Veritas24-7 is a sophisticated information delivery system designed to mimic the distinct roles of a pharmaceutical company's field teams. When a physician logs on, they can interact with two different AI personas.

The first is the AI Sales Representative. This persona is trained to handle commercial discussions, providing company-approved promotional information, details on drug indications, dosing guidance, and resources for patient assistance. It can share approved documents and marketing materials directly on-screen, effectively acting as a digital leave-behind repository that can also hold a conversation.

When a physician's questions pivot from commercial topics to deeper clinical or scientific matters, the platform seamlessly transitions the conversation to the AI Medical Science Liaison. This second persona is designed for evidence-based scientific exchange, discussing clinical trial data, mechanisms of action, and complex scientific inquiries—all grounded in a library of approved medical content and scientific references.

While other AI tools exist to support pharma's commercial and medical teams—platforms from companies like Veeva, IQVIA, and Indegene use AI to analyze data and optimize human engagement strategies—Prismic-AI's claim to be the "first enterprise platform" of its kind appears credible. Its unique proposition is the direct, conversational, on-demand simulation of both the commercial and medical roles through distinct AI personas. It doesn't just suggest the "next-best-action" for a human rep; it seeks to be the next action, available at 3 a.m. when a hospitalist is researching a new therapy between shifts.

Navigating the Gauntlet of Compliance and Trust

The platform's boldest claim is not its technology, but its promise to operate within the pharmaceutical industry's labyrinthine medical, legal, and regulatory requirements. "Compliance is fundamental to Veritas24-7," the company states, a necessary mantra in an industry where a single misstep can lead to severe FDA penalties and reputational damage.

The primary challenge for any generative AI in this space is the risk of "hallucination"—the tendency of AI models to generate confident but inaccurate or entirely fabricated information. In a medical context, this is not a bug but a catastrophic failure. A persona that promotes a drug for an unapproved (off-label) use or fabricates safety data could trigger a regulatory crisis.

Veritas24-7's defense against this is to operate as a "walled garden." The AI personas do not have free access to the open internet; their knowledge is strictly confined to the curated, client-approved scientific and commercial content uploaded to the platform. Every statement, every piece of data shared, is pre-vetted. "The AI isn't creating new knowledge, it's providing a new, conversational interface to a closed library of approved facts," explained a health-tech compliance expert who reviewed the platform's concept. "The innovation is the interface, but the control mechanism is the curated data. That's the only way this could possibly work."

Beyond regulatory compliance lies the equally formidable barrier of physician trust. Will clinicians, trained to rely on peer-reviewed evidence and human expertise, accept a digital persona as a credible source for complex medical information? The answer is likely to be mixed. While studies show a growing, if cautious, acceptance of AI tools in medicine, they also highlight a strong preference for human oversight and interaction.

Prismic-AI appears keenly aware of this, carefully positioning Veritas24-7 as a tool designed to "augment—not replace—existing field-based" teams. This framing is crucial for adoption. The AI rep isn't here to replace a physician's relationship with their trusted human MSL but to handle immediate, straightforward queries, freeing up human experts for more nuanced, high-value strategic discussions.

An Economic Equalizer for the Life Sciences Market

While the technological and regulatory aspects are compelling, the most disruptive potential of Veritas24-7 may lie in its economic implications. Building and deploying a national sales force and a team of highly credentialed MSLs represents one of the largest single expenditures for a pharmaceutical company, often running into the tens or hundreds of millions of dollars annually. This high cost of entry creates a significant barrier for smaller and emerging biotechnology firms.

A platform like Veritas24-7 could fundamentally alter this dynamic. For a fraction of the cost of hiring a national team, a small biotech with a single approved product could theoretically provide comprehensive, 24/7 medical and commercial support to physicians across the country. As Moriarty noted, the platform "provides a scalable and cost-effective way to establish or expand Medical Affairs and Sales capabilities."

This democratization of access could level the playing field, allowing innovation to be judged more on the merit of the scientific data than on the size of the marketing budget. For large, established pharmaceutical companies, the platform offers a different value proposition: efficiency and impact. It allows them to extend the availability of their expert teams without increasing headcount, ensuring that no physician question goes unanswered due to time zones or a rep's busy schedule.

The launch of Veritas24-7 is a clear signal that AI is moving from the back office of data analysis to the front lines of customer engagement. Its success will ultimately depend on a delicate balancing act: delivering a technologically seamless experience while maintaining ironclad compliance and, most importantly, earning the trust of the physicians it was designed to serve.